EcoR1 Capital, LLC
EcoR1 Capital, LLC reported 36 holdings worth US$2.25B as of Sep 30, 2026 (Form 13F)
As of Sep 30, 2026 · Filed Nov 16, 2026
EcoR1 Capital, LLC reported 36 holdings worth US$2.25B as of Sep 30, 2026. Largest: Zymeworks Inc., AnaptysBio, Inc. and CG Oncology, Inc. Filed Nov 16, 2026 (Form 13F).
- Holdings
- 36
- Value as reported
- US$2.25B
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Zymeworks Inc. | 23M | US$608M | 27.0% |
| AnaptysBio, Inc. | 7.88M | US$396M | 17.6% |
| CG Oncology, Inc. | 1.87M | US$133M | 5.9% |
| Eton Pharmaceuticals, Inc. | 2.47M | US$127M | 5.6% |
| First Tracks Biotherapeutics, Inc. | 3.17M | US$113M | 5.0% |
| Aktis Oncology, Inc. | 4.82M | US$93.9M | 4.2% |
| Alto Neuroscience, Inc. | 2.23M | US$57M | 2.5% |
| Lakefront Biotherapeutics | 1.67M | US$49.4M | 2.2% |
| Erasca, Inc. | 2.95M | US$43.2M | 1.9% |
| ORIC Pharmaceuticals, Inc. | 3.03M | US$40.8M | 1.8% |
| Neurogene Inc. | 1.27M | US$35.4M | 1.6% |
| Attovia Therapeutics, Inc. | 2.02M | US$34.7M | 1.5% |
| Fulcrum Therapeutics, Inc. | 6.8M | US$25.2M | 1.1% |
| ADARx Pharmaceuticals, Inc. | 1.15M | US$22.9M | 1.0% |
| Stoke Therapeutics, Inc. | 835K | US$21.7M | 0.96% |
| Zenas BioPharma, Inc. | 790K | US$21.3M | 0.95% |
| Electra Therapeutics, Inc. | 1.7M | US$19.1M | 0.85% |
| Atara Biotherapeutics, Inc. | 1.55M | US$13.2M | 0.59% |
| Capricor Therapeutics, Inc. | 1.38M | US$13M | 0.58% |
| Xencor, Inc. | 500K | US$12.5M | 0.55% |
| Odyssey Therapeutics, Inc. | 556K | US$12.3M | 0.55% |
| Aura Biosciences, Inc. | 1.67M | US$10.5M | 0.46% |
| Nurix Therapeutics, Inc. | 375K | US$8.89M | 0.39% |
| Braveheart Bio, Inc. | 417K | US$8.42M | 0.37% |
| Eikon Therapeutics, Inc. | 856K | US$6.88M | 0.31% |
| Eloxx Pharmaceuticals, Inc. | 400K | US$6.12M | 0.27% |
| Aardvark Therapeutics, Inc. | 720K | US$3.79M | 0.17% |
| BridgeBio Oncology Therapeutics, Inc. | 890K | US$3.65M | 0.16% |
| TCGX Acquisition Corp. | 250K | US$3.13M | 0.14% |
| Zura Bio Limited | 680K | US$2.83M | 0.13% |
| Helix Acquisition Corp. III | 200K | US$2.12M | 0.09% |
| Contineum Therapeutics, Inc. | 64,303 | US$863K | 0.04% |
| MBX Biosciences, Inc. | 0 | US$0 | 0.00% |
| Phathom Pharmaceuticals, Inc. | 0 | US$0 | 0.00% |
| Relay Therapeutics, Inc. | 0 | US$0 | 0.00% |
Source
Download original · View original at SEC
Related